A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Eflapegrastim (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Ifosfamide; Vincristine
- Indications Chemotherapy-induced damage; Febrile neutropenia
- Focus Adverse reactions
- Sponsors Spectrum Pharmaceuticals
- 28 Feb 2024 Planned End Date changed from 1 Oct 2025 to 1 Oct 2027.
- 28 Feb 2024 Planned primary completion date changed from 1 Jul 2025 to 1 Oct 2027.
- 01 Sep 2021 Status changed from not yet recruiting to recruiting.